Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0YXBEH
ADC Name
SHR-A1912
Synonyms
SHR A1912; SHRA1912
   Click to Show/Hide
Organization
Jiangsu Hengrui Pharmaceuticals Co., Ltd.; Shanghai Hengrui Pharmaceutical Co., Ltd.
Drug Status
Phase 1
Indication
In total 1 Indication(s)
B-cell lymphoma [ICD11:2A86]
Phase 1
Antibody Name
Undisclosed
Antigen Name
B-cell antigen receptor complex-associated protein beta chain (CD79B)
  Antigen Info 
Payload Name
Undisclosed
Linker Name
Undisclosed
General Information of The Activity Data Related to This ADC
Identified from the Human Clinical Data
Click To Hide/Show 1 Activity Data Related to This Level
Standard Type NCT Number Clinical Status Clinical Trial Description
Undisclosed  NCT05113069
Phase 1
An open-label, single-arm, multicenter, phase 1 study to estimate the safety, tolerability, pharmacokinetics, and efficacy of SHR-A1912 in patients with b-cell lymphoma.
Full List of Activity Data of This Antibody-drug Conjugate
Identified from the Human Clinical Data
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Related Clinical Trial
NCT Number NCT05113069  Clinical Status Phase 1
Clinical Description An open-label, single-arm, multicenter, phase 1 study to estimate the safety, tolerability, pharmacokinetics, and efficacy of SHR-A1912 in patients with b-cell lymphoma.
References
Ref 1 An Open-Label, Single-Arm, Multicenter, Phase I Study to Estimate the Safety, Tolerability, Pharmacokinetics, and Efficacy of SHR-A1912 in Patients With B-cell Lymphoma

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.